A Randomised, Double-blind, Placebo-controlled, Multi-centre Trial Investigating the Efficacy and Safety of Desmopressin (FE 992026) Orally Disintegrating Tablets During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Japanese Male Subjects
Latest Information Update: 13 Sep 2019
At a glance
- Drugs Desmopressin (Primary)
- Indications Nocturia
- Focus Registrational; Therapeutic Use
- Sponsors Ferring Pharmaceuticals
- 05 Oct 2017 Status changed from not yet recruiting to completed.
- 29 Sep 2016 New trial record